• Ann N Leung, Todd M Bull, Roman Jaeschke, Charles J Lockwood, Phillip M Boiselle, Lynne M Hurwitz, Andra H James, Laurence B McCullough, Yusuf Menda, Michael J Paidas, Henry D Royal, Victor F Tapson, Helen T Winer-Muram, Frank A Chervenak, Dianna D Cody, Michael F McNitt-Gray, Christopher D Stave, Brandi D Tuttle, and ATS/STR Committee on Pulmonary Embolism in Pregnancy.
• Radiology. 2012 Feb 1; 262 (2): 635-46.

BackgroundPulmonary embolism (PE) is a leading cause of maternal mortality in the developed world. Along with appropriate prophylaxis and therapy, prevention of death from PE in pregnancy requires a high index of clinical suspicion followed by a timely and accurate diagnostic approach.MethodsTo provide guidance on this important health issue, a multidisciplinary panel of major medical stakeholders was convened to develop evidence-based guidelines for evaluation of suspected pulmonary embolism in pregnancy using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system. In formulation of the recommended diagnostic algorithm, the important outcomes were defined to be diagnostic accuracy and diagnostic yield; the panel placed a high value on minimizing cumulative radiation dose when determining the recommended sequence of tests.ResultsOverall, the quality of the underlying evidence for all recommendations was rated as very low or low with some of the evidence considered for recommendations extrapolated from studies of the general population. Despite the low quality evidence, strong recommendations were made for three specific scenarios: performance of chest radiography (CXR) as the first radiation-associated procedure; use of lung scintigraphy as the preferred test in the setting of a normal CXR; and performance of computed-tomographic pulmonary angiography (CTPA) rather than digital subtraction angiography (DSA) in a pregnant woman with a nondiagnostic ventilation-perfusion (V/Q) result.DiscussionThe recommendations presented in this guideline are based upon the currently available evidence; availability of new clinical research data and development and dissemination of new technologies will necessitate a revision and update.© RSNA, 2011

14 keywords...

hide…